AAIC 2024 | Looking back over the first year of lecanemab use in AD: benefits and challenges

Suzanne Schindler, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, looks back over the first year of using lecanemab in the treatment of Alzheimer’s disease (AD). She highlights that extra effort has been required to assess which patients are suitable for this treatment. The rates of amyloid-related imaging abnormalities (ARIA) have been as expected, with most patients who experience ARIA being asymptomatic or with mild symptoms. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.